




版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
3/981ValveProsthesisMechanicaltypes:caged-ball,tilting-disk,bi-leafletadvantage:durabilitylimitation:thrombogenicityBioprosthetictypes:heterografts,homograftsadvantage:shorttermanticoagulationlimitation:structuralfailure3/981ValveProsth3/982MechanicalValveProsthesisTypescaged-ball(Starr-Edwards)tilting-disk(Medtronic-Hall)bileaflet(StJude)Advantage:durability(1)Limitation:thrombogenicity1.NEnglJMed1996;335:407-4163/982MechanicalV3/983BioprostheticHeterograftsadvantagelongtermanticoagulationunnecessary(1)limitation:structuralfailureleafletcalcification&tissuedegenerationleadingtovalvularregurgitationstenosisisuncommonrateofporcinevalvedegeneration
26%(aortic),39%(mitral)in10yrs(2)1.NEnglJMed1993;329:524-5292.AnnThoracSurg1990;49:370-3833/983Bioprostheti3/984BioprostheticHomografts1956-firstaorticvalvehomograftwasusedinthedescendingthoracicaortaforaorticregurgitation1962-firstsub-coronaryusehighincidenceofpost-opfailure*
(years) 5 10 15 20survivalrate(%) 85 66 53 38re-operation(%) 22 62 85 95*Circulation1991;84(suppl3):III81-III883/984Bioprostheti3/985BioprostheticHomograftsearlypreservationtechniquesformaldehyde,chlorhexidine,propiolactone,ethyleneoxide,
-irridiation,freezingat-70oCgraftsarenonviablehighincidenceofcusprupture3/985Bioprostheti3/986BioprostheticHomografts
advancesImprovingvalvedurabilitynewerpreservationtechniques:cryopreservationbyliquidnitrogenwithlow-doseantibioticshomovitalgrafts(freshunpreserved)reducedtimeforgraftprocurementdonorratherthanautopsyspecimens3/986Bioprostheti3/987BioprostheticHomografts
UniversityofAlabama1981-1991cryopreservedaorticgraftsin178ptssurvivalrate91%at1year85%at8yearsfreedomfromre-operation95%at8yearsJThoracCardiovascSurg1993;106:154-1653/987Bioprostheti3/988BioprostheticHomografts
PrinceCharlesHsopital1975-1994cryopreservedaorticgraftsin680ptshospitalmortality2.8%survivalrate77%at10year;45%at20yearsfreedomfromre-operation69%at15yearsO’Brian.AnnThoracSurg1996;60:S65-S703/988Bioprostheti3/989Homovitalhomografts
Londongraftsareharvested,storedintissueculturemedium,andusedin3days275graftsimplantedover13years:147subcoronary,128aorticrootnotransmissionofdiseasereportedcumulativesurvival85%at10yrs(94%intheaorticrootgp)freedomfromre-op:91%in10yrsJThoracCardiovascSurg1995;110:186-1933/989Homovitalho3/9810BioprostheticHomografts
implantationtechniquesFreehandscallopedtechniqueretentionofminimaldonortissuetechnicallychallenging,requireexactsizingtopreventregurgitationCylindertechniqueretentionofnativeaorticsinusesandsinotubularjunctionrequirescoronaryreimplantationAnnThoracSurg1996;62:1069-10753/9810Bioprosthet3/9811BioprostheticHomografts
implantationtechniquesMayoClinicseries1985-1994
implantation scalloped cylindernumbers 59 78latemod-sevAR 26% 12%7yrre-oprate 24.2% 11.5%AnnThoracSurg1996;62:1069-10753/9811Bioprosthet3/9812BioprostheticHomografts
cylindertechniquesimprovedoutcomemaintainingthenaturalvalvegeometryandstructureensuresbetteraorticcuspcoaptationreducestheriskofaorticregurgitationAnnThoracSurg1996;62:1069-10753/9812Bioprosthet3/9813The“Rossprocedure”Adoublevalveproceduretransferthepatient’snativepulmonaryvalveintotheaorticpositioninsertahomograftintotheresectedpulmonarypositionlongtermfollow-upof131pts47%survivalat20yrs(age11-52)35%re-op(15%aortic,10%pulmonary)Circulation1997;96:2206-22143/9813The“Rossp3/9814AorticValveHomograftcomplicationsaorticregurgitationisthemajormodeofgraftfailureearlyaorticregurgitation
technicalfactors(sizing,distortion)lateaorticregurgitation
commissuralmalalignment,cuspaldistortion,cuspalprolapsefromrootenlargementcuspaldeteriorationislesscommon3/9814AorticValv3/9815AorticValveHomograftendocarditisLowincidenceofendocarditisaffectinghomografts:6%at15yrs(1)Treatmentofchoiceforprostheticvalveendocarditis(PVE)mortalityforPVEhasbeen20-50%hospitalmortalityreducedto8.3%withhomograftsinthetreatmentofPVE(2)1.AnnThoracSurg1995;60:S65-S702.SeminThoracCardiovascSurg1997;11:53-613/9815AorticValv3/9816AorticValveHomograftanticoagulationMechanicalvalvesriskofthromboembolism,majorbleeding,strokeisapprox3%(1)withINRof2.5-4.9Aortichomograftsanticoagulationisunnecessary1.NEnglJMed1995;333:11-173/9816AorticValv3/9817AorticValveHomograft
ConclusionAdvantageofnotneedinganticoagulationNotyetaperfectvalveAorticregurgitaitonstilloccurswithmodernpreservationtechniquesstructualfailurealsoalimitation,particularlyintheyoungpatient3/9817AorticValv3/9818AorticValveHomograft
ConclusionInolderpatients(age>60),heterograftshavearelativelylowrateofstructuralfailure,theadvantageofhomograftsisminimalSurgicalexpertiserequired;maynotbeavailableatallinstitutions3/9818AorticValv3/9819AorticValveHomograft
indicationsactiveendocarditis,particularlythosewithconcomitantrootabscesscomplexaorticpathology(aneurysmordissection)whenthevalveisnotamenabletorepairorresuspensionyoungpatients(age<60)whenlong-termanticoagualtionisnotdesiredoriscontraindicated3/9819AorticValv3/9820ValveProsthesisMechanicaltypes:caged-ball,tilting-disk,bi-leafletadvantage:durabilitylimitation:thrombogenicityBioprosthetictypes:heterografts,homograftsadvantage:shorttermanticoagulationlimitation:structuralfailure3/981ValveProsth3/9821MechanicalValveProsthesisTypescaged-ball(Starr-Edwards)tilting-disk(Medtronic-Hall)bileaflet(StJude)Advantage:durability(1)Limitation:thrombogenicity1.NEnglJMed1996;335:407-4163/982MechanicalV3/9822BioprostheticHeterograftsadvantagelongtermanticoagulationunnecessary(1)limitation:structuralfailureleafletcalcification&tissuedegenerationleadingtovalvularregurgitationstenosisisuncommonrateofporcinevalvedegeneration
26%(aortic),39%(mitral)in10yrs(2)1.NEnglJMed1993;329:524-5292.AnnThoracSurg1990;49:370-3833/983Bioprostheti3/9823BioprostheticHomografts1956-firstaorticvalvehomograftwasusedinthedescendingthoracicaortaforaorticregurgitation1962-firstsub-coronaryusehighincidenceofpost-opfailure*
(years) 5 10 15 20survivalrate(%) 85 66 53 38re-operation(%) 22 62 85 95*Circulation1991;84(suppl3):III81-III883/984Bioprostheti3/9824BioprostheticHomograftsearlypreservationtechniquesformaldehyde,chlorhexidine,propiolactone,ethyleneoxide,
-irridiation,freezingat-70oCgraftsarenonviablehighincidenceofcusprupture3/985Bioprostheti3/9825BioprostheticHomografts
advancesImprovingvalvedurabilitynewerpreservationtechniques:cryopreservationbyliquidnitrogenwithlow-doseantibioticshomovitalgrafts(freshunpreserved)reducedtimeforgraftprocurementdonorratherthanautopsyspecimens3/986Bioprostheti3/9826BioprostheticHomografts
UniversityofAlabama1981-1991cryopreservedaorticgraftsin178ptssurvivalrate91%at1year85%at8yearsfreedomfromre-operation95%at8yearsJThoracCardiovascSurg1993;106:154-1653/987Bioprostheti3/9827BioprostheticHomografts
PrinceCharlesHsopital1975-1994cryopreservedaorticgraftsin680ptshospitalmortality2.8%survivalrate77%at10year;45%at20yearsfreedomfromre-operation69%at15yearsO’Brian.AnnThoracSurg1996;60:S65-S703/988Bioprostheti3/9828Homovitalhomografts
Londongraftsareharvested,storedintissueculturemedium,andusedin3days275graftsimplantedover13years:147subcoronary,128aorticrootnotransmissionofdiseasereportedcumulativesurvival85%at10yrs(94%intheaorticrootgp)freedomfromre-op:91%in10yrsJThoracCardiovascSurg1995;110:186-1933/989Homovitalho3/9829BioprostheticHomografts
implantationtechniquesFreehandscallopedtechniqueretentionofminimaldonortissuetechnicallychallenging,requireexactsizingtopreventregurgitationCylindertechniqueretentionofnativeaorticsinusesandsinotubularjunctionrequirescoronaryreimplantationAnnThoracSurg1996;62:1069-10753/9810Bioprosthet3/9830BioprostheticHomografts
implantationtechniquesMayoClinicseries1985-1994
implantation scalloped cylindernumbers 59 78latemod-sevAR 26% 12%7yrre-oprate 24.2% 11.5%AnnThoracSurg1996;62:1069-10753/9811Bioprosthet3/9831BioprostheticHomografts
cylindertechniquesimprovedoutcomemaintainingthenaturalvalvegeometryandstructureensuresbetteraorticcuspcoaptationreducestheriskofaorticregurgitationAnnThoracSurg1996;62:1069-10753/9812Bioprosthet3/9832The“Rossprocedure”Adoublevalveproceduretransferthepatient’snativepulmonaryvalveintotheaorticpositioninsertahomograftintotheresectedpulmonarypositionlongtermfollow-upof131pts47%survivalat20yrs(age11-52)35%re-op(15%aortic,10%pulmonary)Circulation1997;96:2206-22143/9813The“Rossp3/9833AorticValveHomograftcomplicationsaorticregurgitationisthemajormodeofgraftfailureearlyaorticregurgitation
technicalfactors(sizing,distortion)lateaorticregurgitation
commissuralmalalignment,cuspaldistortion,cuspalprolapsefromrootenlargementcuspaldeteriorationislesscommon3/9814AorticValv3/9834AorticValveHomograftendocarditisLowincidenceofendocarditisaffectinghomografts:6%at15yrs(1)Treatmentofchoiceforprostheticvalveendocarditis(PVE)mortalityforPVEhasbeen20-50%hospitalmortalityreducedto8.3%withhomograftsinthetreatmentofPVE(2)1.AnnThoracSurg1995;60:S65-S702.SeminThoracCardiovascSurg1997;11
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 2025年药剂师执业资格考试题及答案安排
- TechnoDye-498-505-生命科学试剂-MCE
- Griseorhodin-A-生命科学试剂-MCE
- 2025年企业文化发展考试题及答案分析
- 2025年人机协作与智能制造考试试题及答案
- 2025年经济法与商业伦理考试试题及答案
- 2025年房地产估价师考试试卷及答案说明
- 2025年公共卫生管理员考试试卷及答案
- 数学思维训练课:实数运算与逻辑思维培养
- 语文知识小课堂:古代诗歌欣赏
- 临终关怀中的文化敏感性
- 运动改造大脑阅读记录
- 技术开发合同免税政策
- 租赁国企用地合同范本
- DL∕T 2011-2019 大型发电机定子绕组现场更换处理试验规程
- 2024年江苏省南京玄武区八下英语期末考试试题含答案
- 从黄土高原视角品黄河生态变迁智慧树知到期末考试答案章节答案2024年西北工业大学
- 广东省东莞市2023-2024学年高二下学期7月期末英语试题
- 2024内蒙古森工集团第二批工作人员招聘【重点基础提升】模拟试题(共500题)附带答案详解
- 黑龙江省高校毕业生“三支一扶”计划招募笔试真题2021
- 河北省建设项目概算其他费用定额
评论
0/150
提交评论